Cellares Adds PACT Pharma to its Early Access Partnership Program
USA - English
- Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount
- PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center
News provided by
Share this article
SOUTH SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/
Cellares Corporation, a company focused on revolutionizing cell therapy manufacturing, announced that PACT Pharma, Inc., a clinical-stage company developing transformational personalized NeoTCR-T cell therapies for the eradication of solid tumors, has joined its Early Access Partnership Program (EAPP). PACT Pharma is the second collaborator and first industry organization to join its EAPP, following Fred Hutchinson Cancer Research Center. Under the terms of
O MIRANTE | Nersant presta apoio especializado a empreendedores e ajuda na criação de empresas
omirante.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from omirante.pt Daily Mail and Mail on Sunday newspapers.
O MIRANTE | Workshops da NERSANT preparam empresas para entrada no mercado
omirante.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from omirante.pt Daily Mail and Mail on Sunday newspapers.
O MIRANTE | NERSANT dá apoio especializado a empreendedores e apoia criação de empresas
omirante.pt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from omirante.pt Daily Mail and Mail on Sunday newspapers.